case,ID,colrev_origin,ENTRYTYPE,author,year,title,volume,number,pages,abstract,doi,isbn,url,colrev_status,author_full,container_title,first_author,short_container_title
source_1.bib/0000000510;source_1.bib/0000000509,509,source_1.bib/0000000509,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=https://link.springer.com/content/pdf/10.1007%2Fs00125-014-3355-0.pdf,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000000510;source_1.bib/0000000509,510,source_1.bib/0000000510,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=https://link.springer.com/content/pdf/10.1007%2Fs00125-014-3355-0.pdf,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000000510;source_1.bib/0000001253,510,source_1.bib/0000000510,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=https://link.springer.com/content/pdf/10.1007%2Fs00125-014-3355-0.pdf,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000000510;source_1.bib/0000001253,1253,source_1.bib/0000001253,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,57,1  1,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=71595521,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000000510;source_1.bib/0000001544,510,source_1.bib/0000000510,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=https://link.springer.com/content/pdf/10.1007%2Fs00125-014-3355-0.pdf,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000000510;source_1.bib/0000001544,1544,source_1.bib/0000001544,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000000510;source_1.bib/0000001716,510,source_1.bib/0000000510,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=https://link.springer.com/content/pdf/10.1007%2Fs00125-014-3355-0.pdf,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000000510;source_1.bib/0000001716,1716,source_1.bib/0000001716,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001254;source_1.bib/0000000509,509,source_1.bib/0000000509,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=https://link.springer.com/content/pdf/10.1007%2Fs00125-014-3355-0.pdf,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001254;source_1.bib/0000000509,1254,source_1.bib/0000001254,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,57,1  1,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 0.001. atherosclerotic lesions were also observed in the coronary arteries. the four major coronary arteries increased in area with cholesterol feeding 1.14 0.12 vs. 0.81 0.06 mm2 while anagliptin treatment attenuated this change 0.87 0.07 mm2. the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm2. the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=71595520,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001254;source_1.bib/0000001253,1253,source_1.bib/0000001253,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,57,1  1,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=71595521,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001254;source_1.bib/0000001253,1254,source_1.bib/0000001254,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,57,1  1,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 0.001. atherosclerotic lesions were also observed in the coronary arteries. the four major coronary arteries increased in area with cholesterol feeding 1.14 0.12 vs. 0.81 0.06 mm2 while anagliptin treatment attenuated this change 0.87 0.07 mm2. the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm2. the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=71595520,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001254;source_1.bib/0000001544,1254,source_1.bib/0000001254,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,57,1  1,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 0.001. atherosclerotic lesions were also observed in the coronary arteries. the four major coronary arteries increased in area with cholesterol feeding 1.14 0.12 vs. 0.81 0.06 mm2 while anagliptin treatment attenuated this change 0.87 0.07 mm2. the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm2. the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=71595520,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001254;source_1.bib/0000001544,1544,source_1.bib/0000001544,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001254;source_1.bib/0000001716,1254,source_1.bib/0000001254,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,57,1  1,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 0.001. atherosclerotic lesions were also observed in the coronary arteries. the four major coronary arteries increased in area with cholesterol feeding 1.14 0.12 vs. 0.81 0.06 mm2 while anagliptin treatment attenuated this change 0.87 0.07 mm2. the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm2. the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=71595520,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001254;source_1.bib/0000001716,1716,source_1.bib/0000001716,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001546;source_1.bib/0000000509,509,source_1.bib/0000000509,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=https://link.springer.com/content/pdf/10.1007%2Fs00125-014-3355-0.pdf,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001546;source_1.bib/0000000509,1546,source_1.bib/0000001546,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001546;source_1.bib/0000001253,1253,source_1.bib/0000001253,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,57,1  1,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=71595521,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001546;source_1.bib/0000001253,1546,source_1.bib/0000001546,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001546;source_1.bib/0000001544,1544,source_1.bib/0000001544,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001546;source_1.bib/0000001544,1546,source_1.bib/0000001546,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001546;source_1.bib/0000001716,1546,source_1.bib/0000001546,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001546;source_1.bib/0000001716,1716,source_1.bib/0000001716,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001718;source_1.bib/0000000509,509,source_1.bib/0000000509,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=https://link.springer.com/content/pdf/10.1007%2Fs00125-014-3355-0.pdf,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001718;source_1.bib/0000000509,1718,source_1.bib/0000001718,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001718;source_1.bib/0000001253,1253,source_1.bib/0000001253,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,57,1  1,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,10.1007/s00125-014-3355-0,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed15&NEWS=N&AN=71595521,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001718;source_1.bib/0000001253,1718,source_1.bib/0000001718,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001718;source_1.bib/0000001544,1544,source_1.bib/0000001544,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001718;source_1.bib/0000001544,1718,source_1.bib/0000001718,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
source_1.bib/0000001718;source_1.bib/0000001716,1716,source_1.bib/0000001716,article,terasaki nagashima hiromura notomi hirano,2014,a dpp 4 inhibitor remarkably suppresses foam cell formation in peritoneal macrophages obtained from db db diabetic mice comparison with a sglt2 inhibitor and pioglitazone,1,,354,background and aims we reported that a dipeptidyl peptidase4 inhibitor dpp4i confer an antiatherosclerotic effect in diabetic apolipoprotein e null mice with significant suppression of foam cell formation in macrophagesmphi. however it remains to be elucidated whether a dpp4i exerts antiatherogenic properties beyond glycaemic control. we evaluated the suppressive effect of dpp4i on foam cell formation in mphi obtained from dbdb diabetic mice and compared with other glucoselowering agents a sodiumglucose cotransporter sglt2inhibitor and pioglitazone. materials and methods male dbdb mice at 9weekold were fed normal diet containing none n23 alogliptin 0.02 ww n12 pioglitazone 0.02 n12 or ipragliflozin 0.0014 n13 for 4 weeks. in subset of animals at age of 13 weeks glucose 0.5gkg body weight was administrated orally and bled 0 15 30 60 and 120 min thereafter ogtt. peritoneal mphi were obtained from mice at age of 13 weeks after the injection of thioglycollate. foam cell formation was determined by the incorporation of 3holeate into cholesteryloleate stimulated by oxidizedldl in mphi. cd36 and acetylcoa acetyltransferaseacat1 gene expression was measured by rtpcr. results food and water intakes were comparable among treated groups whereas final body weight was increased in piogitazone group by 6 and decreased in ipragliflozin group by 5 compared with nontreated control group. pioglitazone and ipragliflozin decreased fasting blood glucose fbg hba1c and glucoseauc in ogtt compared with control groupfbg6.10.4 10.01.6 and 19.41.8mmoll hba1c 5.20.2 5.70.3 and 8.40.2 auc 790280 2123260 4183293mmollxmin respectively. alogliptin group exhibited mild reductions of fbg hba1c and auc 16.01.3mmoll 7.00.4 and 3413463mmollxmin. despite mild amelioration of glycemic control with alogliptin the mphi foam cell formation was 36 decreased which was comparable to those with pioglitazone or ipragliflozin 35 and 30 respectively. foam cell formation was critically regulated by glycemic control hba1c in each group r0.700.94 p0.02. the linear regression curves were similar between control and ipragliflozin groups. alogliptin group distributed below the regression curves made by control and ipragliflozin groups indicating that foam cell formation of alogliptin group is further suppressed than corresponded hba1c. gene expressions of cd36 and acat1 were upregulated in dbdb mice. alogliptin treatment decreased gene expression of cd36 and acat1. conclusion a pioglitazone and a sglt2inihibitor both suppress foam cell formation in obese diabetic mice by substantial glucoselowering effect whereas dpp4inhibitor remarkably suppresses foam cell formation despite mild amelioration of glycaemic control suggesting a pleiotropic effect of dpp4 inhibitor on atherogenesis beyond glucose. figure presented,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595521 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+remarkably+suppresses+foam+cell+formation+in+peritoneal+macrophages+obtained+from+db%2Fdb+diabetic+mice%2C+comparison+with+a+SGLT2+inhibitor+and+pioglitazone&rft.aulast=Terasaki&rft.isbn=,md_processed,"terasaki, m and nagashima, m and hiromura, m and notomi, k and hirano, t",diab,terasaki,d
source_1.bib/0000001718;source_1.bib/0000001716,1718,source_1.bib/0000001718,article,hirano yamashita takahashi hashimoto goto,2014,a dpp 4 inhibitor suppresses atherosclerotic lesions in the aorta and coronary arteries with decrease of macrophage infiltration in cholesterolfed rabbits,1,,354,background and aims several studies have demonstrated suppression of atherosclerosis by dipeptidyl peptidase4 dpp4 inhibitors in hypercholesterolemic mice. however it remains unknown whether dpp4 inhibitors might also exert antiatherogenic effects in bigger animals. we examined the effect of anagliptin a dpp4 inhibitor on the development of atherosclerosis in the aorta and coronary arteries in cholesterolfed rabbits. materials and methods japanese white rabbits were fed either a normal diet or a diet containing 0.5 cholesterol. the cholesterolfed rabbits were given drinking water not mixed n 18 or mixed with 3 mgml of anagliptin n 16 for 12 weeks. the lipoprotein fractions were measured by highperformance liquid chromatography. the serum oxidative stress markers 8hydroxy2deoxyguanosine ohdg and malondealdehyde mda were measured by elisa and tbars respectively. inflammatory cytokine gene expressions in the carotid artery were quantified by real timeqpcr. we measured the lesion area in the aorta and the coronary arteries in seven crosssections of the heart. values were expressed as mean se. results dietary cholesterol intake led to a marked increase of the serum totalcholesterol tc level 37.9 3.9 vs. 0.59 0.04 mmoll with the most striking increase seen in the vldl fraction 3080 nm among the major lipoproteins. no significant changes of the body weight water intake hba1c serum lipids and lipoproteins or glucose response to intravenous glucose loading were observed following the administration of anagliptin. the plasma dpp4 activity was suppressed by 86 and the plasma active glp1 levels doubled. dietary cholesterol intake resulted in the development of severe atherosclerosis in the aorta with a ratio of the lesion area to the total aortic surface areas of 22.0 2.3 and anagliptin treatment induced marked suppression of the percent lesion area to 8.6 2.1 p 2 while anagliptin treatment attenuated this change 0.87 0.07 mm 2 . the intimal formation in the coronary arteries in the cholesterolfed mice was attenuated by anagliptin treatment 0.04 0.02 vs. 0.13 0.05 mm 2 . the alphasmapositive and macrophagepositive areas in the coronary arteries were suppressed 54 and 78 respectively by anagliptin treatment p 0.05. notably the ratio of the macrophage area to the plaque area was substantially decreased by 83. the serum 8ohdg and mda showed no significant changes following the anagliptin treatment. however the arterial gene expressions of the inflammatory cytokines tnfalpha and interleukin6 were markedly reduced by approximately 90 p 0.0010.05 and the expressions of macrophage chemoattractant protein1and cd26 in the carotid arteries were partially reduced by about 30 following the anagliptin administration. conclusion our study demonstrated for the first time that a dpp4 inhibitor suppressed the development of atherosclerosis in the aorta and coronary arteries in bigger animals than rodents by inhibiting the inflammatory responses in the vessels,,0012-186x,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71595520 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed15&rft.genre=article&rft_id=info:doi/10.1007%2Fs00125-014-3355-0&rft_id=info:pmid/&rft.issn=0012-186X&rft.volume=57&rft.issue=1+SUPPL.+1&rft.spage=S354&rft.pages=S354&rft.date=2014&rft.jtitle=Diabetologia&rft.atitle=A+DPP-4+inhibitor+suppresses+atherosclerotic+lesions+in+the+aorta+and+coronary+arteries+with+decrease+of+macrophage+infiltration+in+cholesterolfed+rabbits&rft.aulast=Hirano&rft.isbn=,md_processed,"hirano, t and yamashita, s and takahashi, m and hashimoto, h and goto, m",diab,hirano,d
